BR9913472A - Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas - Google Patents

Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas

Info

Publication number
BR9913472A
BR9913472A BR9913472-1A BR9913472A BR9913472A BR 9913472 A BR9913472 A BR 9913472A BR 9913472 A BR9913472 A BR 9913472A BR 9913472 A BR9913472 A BR 9913472A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
new
manufacturing processes
sodium alendronate
alendronate
Prior art date
Application number
BR9913472-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR9913472A publication Critical patent/BR9913472A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9913472-1A 1998-08-27 1999-08-27 Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas BR9913472A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BR9913472A true BR9913472A (pt) 2002-03-05

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913472-1A BR9913472A (pt) 1998-08-27 1999-08-27 Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas

Country Status (30)

Country Link
US (2) US6281381B1 (https=)
EP (1) EP1107974B1 (https=)
JP (2) JP2002523514A (https=)
KR (2) KR20070034132A (https=)
AT (1) ATE334993T1 (https=)
AU (1) AU5698899A (https=)
BG (1) BG65329B1 (https=)
BR (1) BR9913472A (https=)
CA (1) CA2341459A1 (https=)
CZ (1) CZ2001629A3 (https=)
DE (1) DE69932620T2 (https=)
DK (1) DK1107974T3 (https=)
EA (1) EA002739B1 (https=)
EE (1) EE04552B1 (https=)
ES (1) ES2270613T3 (https=)
HR (1) HRP20010129A2 (https=)
HU (1) HUP0203078A3 (https=)
IL (1) IL141423A (https=)
IS (1) IS5864A (https=)
LT (1) LT4888B (https=)
LV (1) LV12720B (https=)
NO (1) NO20010957L (https=)
NZ (1) NZ510682A (https=)
PL (1) PL346347A1 (https=)
PT (1) PT1107974E (https=)
RO (1) RO122854B1 (https=)
SI (1) SI20581B (https=)
SK (1) SK2482001A3 (https=)
WO (1) WO2000012517A1 (https=)
YU (1) YU14701A (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK2283825T3 (da) 2004-05-24 2022-06-27 Theramex Hq Uk Ltd Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2221844A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations

Also Published As

Publication number Publication date
LV12720B (en) 2002-02-20
EA200100184A1 (ru) 2001-10-22
US6281381B1 (en) 2001-08-28
RO122854B1 (ro) 2010-03-30
ATE334993T1 (de) 2006-08-15
SK2482001A3 (en) 2002-01-07
BG65329B1 (bg) 2008-02-29
NO20010957L (no) 2001-04-26
WO2000012517A1 (en) 2000-03-09
JP2009143955A (ja) 2009-07-02
LT2001016A (en) 2001-10-25
PL346347A1 (en) 2002-02-11
DK1107974T3 (da) 2006-10-30
EE04552B1 (et) 2005-10-17
NO20010957D0 (no) 2001-02-26
KR20070034132A (ko) 2007-03-27
BG105292A (en) 2001-12-29
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
HUP0203078A2 (hu) 2003-01-28
IL141423A0 (en) 2002-03-10
CA2341459A1 (en) 2000-03-09
DE69932620T2 (de) 2006-12-14
IS5864A (is) 2001-02-26
DE69932620D1 (de) 2006-09-14
LV12720A (lv) 2001-09-20
US6696601B2 (en) 2004-02-24
LT4888B (lt) 2002-02-25
WO2000012517A9 (en) 2000-07-13
AU5698899A (en) 2000-03-21
EP1107974A1 (en) 2001-06-20
HUP0203078A3 (en) 2005-01-28
IL141423A (en) 2005-09-25
NZ510682A (en) 2003-09-26
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
SI20581B (sl) 2008-06-30
EA002739B1 (ru) 2002-08-29
PT1107974E (pt) 2006-10-31
YU14701A (sh) 2003-01-31
CZ2001629A3 (cs) 2001-08-15
ES2270613T3 (es) 2007-04-01
EE200100126A (et) 2002-06-17
SI20581A (sl) 2001-12-31
EP1107974B1 (en) 2006-08-02
JP2002523514A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
BR9913472A (pt) Novas formas hidratadas de alendronato de sódio, seus processos de fabricação e suas composições farmacêuticas
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
BR9916307A (pt) Derivados quinolina
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
PT782449E (pt) Processo de fabrico de unidades de dosagem por granulacao humida
BR9608996A (pt) Bloco para a construção sem argamassa de uma parede
BR9911884A (pt) Preparação farmacêutica
IT8721109A0 (it) Elemento di quarzo fuso da impiegare nella fabbricazione di semiconduttori.
NO994431L (no) Ny formulering
BR9907025A (pt) Polissacarìdeos sintéticos, processo para sua preparação e composições farmacêuticas que contêm os mesmos
FI880274L (fi) Poroest skiktsilikat/ natriumsulfat-agglomerat.
TR199900548A3 (tr) Düsük kesme kuvvetli taneleme kullanilarak dozaj birimlerinin yapimi.
ES2025068B3 (es) Procedimiento para la fabricacion de piezas de construccion curvadas en forma de concha y planas.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
BR9610090A (pt) Material em bloco na forma de treliça
NO960272D0 (no) Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
FI972265A0 (fi) Menetelmä cefotaksimin valmistamiseksi ja uusia natriumsuoloja
ATE125541T1 (de) Reine kristalline form von rifapentin.
FI950818L (fi) Uudet substituoidut sulfoniamidit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
NO894516L (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.
NO901892D0 (no) Fremgangsmaate for fremstilling av (2,1-c)(1,3)-benzodiazepiner og deres anvendelse som medikamenter.
HK1037175A (en) Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
ES1040613Y (es) Bloque de suela y planta ortopedica en una sola pieza para la fabricacion de calzado.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements